The firm reported that its full-year 2024 revenues were up slightly as a rise in the diagnostics business was mostly offset by a decline in life sciences business.

The firm reported that its full-year 2024 revenues were up slightly as a rise in the diagnostics business was mostly offset by a decline in life sciences business.

Revvity expects full-year earnings in the range of $4.90 to $5 per share, with revenue in the range of $2.8 billion to $2.85 billion. This story was generated by Automated Insights ...

Wednesday’s fatal crash of a civilian plane and military helicopter at Reagan National Airport may reflect rising stresses on ...

Thermo Fisher Scientific on Thursday forecast annual profit above Wall Street estimates, banking on improved demand for its ...

Thermo Fisher Scientific (NYSE:TMO) traded higher on Thursday after exceeding Street forecasts with its Q4 2024 financials, ...